Innovative Non-Invasive 'Liquid Biopsy' Method to Capture Circulating Tumor Cells from Blood Samples for Genetic Testing

“Researchers seek partners to commercialize a clinically proven non-invasive fluorescence virus-guided capture system of human colorectal circulating tumor cells (CTCs) from blood samples for genetic testing. This non-invasive companion diagnostics is important for personalized targeted cancer therapy.”

Editor’s note: Cells sometimes break off of a tumor and enter the bloodstream of a patient; these cells are known as “circulating tumor cells” (CTCs). Researchers have developed a new blood test for CTCs that could reveal information about which treatments might work best for a patient. In particular, the test could pinpoint genetic mutations in the tumor cells that would indicate whether certain targeted therapies might work for a patient. The test is notable because it only requires a blood sample from a patient, instead of an invasive surgical biopsy to retrieve cells directly from a tumor. The researchers who developed the test are hoping to work with partners to help them commercialize the test and make it widely available to patients.


Few Circulating Cancer Cells Could Cue Risk of Metastases

“A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients’ chances of survival, say researchers. Metastasis accounts for an estimated 90 percent of cancer deaths. For decades, researchers tried to develop a way to gauge a cancer’s risk of metastasizing from a blood sample — the long-sought-after liquid biopsy.”


Few Circulating Cancer Cells Could Cue Risk of Metastases

“A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients’ chances of survival, say researchers. Metastasis accounts for an estimated 90 percent of cancer deaths. For decades, researchers tried to develop a way to gauge a cancer’s risk of metastasizing from a blood sample — the long-sought-after liquid biopsy.”


Few Circulating Cancer Cells Could Cue Risk of Metastases

“A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients’ chances of survival, say researchers. Metastasis accounts for an estimated 90 percent of cancer deaths. For decades, researchers tried to develop a way to gauge a cancer’s risk of metastasizing from a blood sample — the long-sought-after liquid biopsy.”


'Liquid Biopsy' Offers New Way to Track Lung Cancer

“Scientists have shown how a lung cancer patient’s blood sample could be used to monitor and predict their response to treatment – paving the way for personalised medicine for the disease.

“The recent study, published in the journal Nature Medicine, also offers a method to test new therapies in the lab and to better understand how tumours become resistant to drugs.

“Small cell lung cancer (SCLC) is an aggressive disease with poor survival and new treatments are desperately needed. In many cases the tumour is inoperable and biopsies are difficult to obtain, giving scientists few samples with which to study the disease.”


Sidestepping the Biopsy With New Tools to Spot Cancer

“For people with cancer or suspected cancer, the biopsy is a necessary evil — an uncomfortable and somewhat risky procedure to extract tissue for diagnosis or analysis.

“Lynn Lewis, a breast cancer patient in Brooklyn, has had her cancer analyzed an easier way: simple blood tests that are being called ‘liquid biopsies.’

“Telltale traces of a tumor are often present in the blood. These traces — either intact cancer cells or fragments of tumor DNA — are present in minuscule amounts, but numerous companies are now coming to market with sophisticated tests that can detect and analyze them.”


Sidestepping the Biopsy With New Tools to Spot Cancer

“For people with cancer or suspected cancer, the biopsy is a necessary evil — an uncomfortable and somewhat risky procedure to extract tissue for diagnosis or analysis.

“Lynn Lewis, a breast cancer patient in Brooklyn, has had her cancer analyzed an easier way: simple blood tests that are being called ‘liquid biopsies.’

“Telltale traces of a tumor are often present in the blood. These traces — either intact cancer cells or fragments of tumor DNA — are present in minuscule amounts, but numerous companies are now coming to market with sophisticated tests that can detect and analyze them.”


Sidestepping the Biopsy With New Tools to Spot Cancer

“For people with cancer or suspected cancer, the biopsy is a necessary evil — an uncomfortable and somewhat risky procedure to extract tissue for diagnosis or analysis.

“Lynn Lewis, a breast cancer patient in Brooklyn, has had her cancer analyzed an easier way: simple blood tests that are being called ‘liquid biopsies.’

“Telltale traces of a tumor are often present in the blood. These traces — either intact cancer cells or fragments of tumor DNA — are present in minuscule amounts, but numerous companies are now coming to market with sophisticated tests that can detect and analyze them.”


Liquid Biopsy: Monitoring Cancer-Genetics in the Blood

“Tumour cells release circulating free DNA (cfDNA) into the blood, but the majority of circulating DNA is often not of cancerous origin, and detection of cancer-associated alleles in the blood has long been impossible to achieve. Technological advances have overcome these restrictions, making it possible to identify both genetic and epigenetic aberrations. A liquid biopsy, or blood sample, can provide the genetic landscape of all cancerous lesions (primary and metastases) as well as offering the opportunity to systematically track genomic evolution. This Review will explore how tumour-associated mutations detectable in the blood can be used in the clinic after diagnosis, including the assessment of prognosis, early detection of disease recurrence, and as surrogates for traditional biopsies with the purpose of predicting response to treatments and the development of acquired resistance.”